Graig Suvannavejh
Stock Analyst at Mizuho
(2.24)
# 2,613
Out of 4,873 analysts
149
Total ratings
43.36%
Success rate
-5.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMRX Immuneering | Maintains: Outperform | $8 → $10 | $2.44 | +309.84% | 2 | Jun 18, 2025 | |
| INSM Insmed | Maintains: Outperform | $96 → $110 | $105.42 | +4.34% | 7 | Jun 11, 2025 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $12 → $11 | $3.73 | +194.91% | 2 | May 20, 2025 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Outperform | $30 → $26 | $8.27 | +214.39% | 5 | May 16, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $44 → $48 | $31.93 | +50.35% | 18 | May 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $30 → $20 | $17.62 | +13.51% | 7 | May 14, 2025 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Outperform | $7 → $8 | $5.02 | +59.36% | 7 | May 14, 2025 | |
| IMCR Immunocore Holdings | Maintains: Neutral | $38 → $33 | $31.12 | +6.04% | 8 | Apr 7, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $212 → $216 | $101.65 | +112.49% | 21 | Mar 27, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Outperform | $3 → $1.5 | $0.24 | +518.81% | 2 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $2.21 | +243.89% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $7.89 | +837.90% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $0.5 | $0.30 | +68.92% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $49 | $52.80 | -7.20% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $21.42 | +133.43% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $0.75 | +2,580.97% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $5.42 | +195.48% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $22 | $2.17 | +913.82% | 4 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $3.68 | +171.74% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $9 | $1.38 | +554.55% | 4 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $64 | $1.67 | +3,732.34% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $2.88 | -65.22% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $7.94 | +88.92% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $62.15 | -43.68% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $3.64 | +119.78% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $32.64 | +74.63% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $36.56 | -86.32% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $5.59 | +508.23% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $3.90 | +617.95% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $14.18 | +118.62% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $0.29 | +6,451.72% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $1.80 | +163.89% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $14.40 | +150.00% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $27.05 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $0.84 | +4,304.76% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $106.76 | +19.90% | 1 | Sep 14, 2020 |
Immuneering
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $2.44
Upside: +309.84%
Insmed
Jun 11, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $105.42
Upside: +4.34%
Corvus Pharmaceuticals
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $3.73
Upside: +194.91%
EyePoint Pharmaceuticals
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $8.27
Upside: +214.39%
Harmony Biosciences Holdings
May 15, 2025
Maintains: Outperform
Price Target: $44 → $48
Current: $31.93
Upside: +50.35%
Apellis Pharmaceuticals
May 14, 2025
Maintains: Neutral
Price Target: $30 → $20
Current: $17.62
Upside: +13.51%
Amylyx Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $5.02
Upside: +59.36%
Immunocore Holdings
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $31.12
Upside: +6.04%
Axsome Therapeutics
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $101.65
Upside: +112.49%
Adaptimmune Therapeutics
Nov 27, 2024
Maintains: Outperform
Price Target: $3 → $1.5
Current: $0.24
Upside: +518.81%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $2.21
Upside: +243.89%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $7.89
Upside: +837.90%
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.30
Upside: +68.92%
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $52.80
Upside: -7.20%
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $21.42
Upside: +133.43%
Jul 8, 2024
Initiates: Outperform
Price Target: $20
Current: $0.75
Upside: +2,580.97%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $5.42
Upside: +195.48%
Apr 29, 2024
Maintains: Buy
Price Target: $40 → $22
Current: $2.17
Upside: +913.82%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $3.68
Upside: +171.74%
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $1.38
Upside: +554.55%
Aug 23, 2023
Reiterates: Neutral
Price Target: $64
Current: $1.67
Upside: +3,732.34%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $2.88
Upside: -65.22%
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $7.94
Upside: +88.92%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $62.15
Upside: -43.68%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $3.64
Upside: +119.78%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $32.64
Upside: +74.63%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $36.56
Upside: -86.32%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $5.59
Upside: +508.23%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $3.90
Upside: +617.95%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $14.18
Upside: +118.62%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $0.29
Upside: +6,451.72%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $1.80
Upside: +163.89%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $14.40
Upside: +150.00%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $27.05
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $0.84
Upside: +4,304.76%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $106.76
Upside: +19.90%